U.S. AUG NAHB Housing Market Index Actual 32.00, Previous 32.00.

U.S. AUG NAHB Housing Market Index Actual 32.00, Previous 32.00.

Jerusalem, Sept. 15, 2025 — Entera Bio Ltd. (NASDAQ: ENTX), a leading developer of oral peptides and protein replacement therapies, presented positive pharmacokinetic (PK) data for its first-in-class oral GLP-2 tablet treatment at the 47th European Society for Clinical Nutrition & Metabolism (ESPEN) Congress in Prague, Czech Republic. The data, which was presented in a poster titled "A First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome," demonstrated significant advancements in the treatment paradigm for patients with Short Bowel Syndrome (SBS).

Entera Bio, in collaboration with OPKO Health, Inc., has been developing oral peptide candidates for intestinal malabsorption syndromes using OPKO's proprietary long-acting GLP-2 analog (OPK-8801003) and Entera's N-Tab™ oral peptide platform. The current standard of care for SBS, Gattex® (teduglutide), requires daily subcutaneous injections, which can be challenging for patients to comply with. The oral GLP-2 tablet candidate, OPK-8801003, has the potential to transform treatment by offering a less-invasive administration method.

Key data presented at ESPEN included an extended half-life of approximately 15 hours in minipigs, representing an 18-fold improvement over teduglutide's half-life of 0.85 hours in the same species. The oral tablet also demonstrated robust oral bioavailability, with peak plasma concentrations reaching ~200 ng/ml (Cmax), substantially exceeding the reported Cmax of 36.8 ng/ml for daily 0.05 mg/kg teduglutide subcutaneous injection in humans. The sustained exposure supported once-daily oral dosing, and no signs of toxicity were observed in the preclinical studies.

Short Bowel Syndrome (SBS) is a rare and potentially life-threatening condition affecting approximately 30,000 patients across the U.S. and EU. Current annual sales of Gattex® total roughly $800 million. The condition is characterized by a reduced ability to absorb nutrients and fluids, leading to malnutrition and unintended weight loss. The development of an oral GLP-2 tablet could significantly improve the quality of life for SBS patients by offering a more convenient and accessible treatment option.

About Entera Bio
Entera Bio is a clinical stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs. The company leverages its proprietary technology platform (N-Tab™) and pipeline of first-in-class oral peptide programs targeting PTH(1-34), GLP-1, and GLP-2. Entera's most advanced product candidate, EB613, is being developed as the first oral, osteoanabolic (bone building) once-daily tablet treatment for post-menopausal women with low BMD and high-risk osteoporosis.

References
Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congress^[1] https://www.globenewswire.com/news-release/2025/09/15/3150045/0/en/Entera-Bio-Reports-Positive-PK-Data-for-First-in-Class-Oral-GLP-2-Tablet-Treatment-for-Patients-with-Short-Bowel-Syndrome-at-the-2025-ESPEN-Congress.html
Bajaj Housing Finance to issue 3-year bonds, bankers say^[2] https://www.tradingview.com/news/reuters.com,2025:newsml_L3N3UZ0C6:0-bajaj-housing-finance-to-issue-3-year-bonds-bankers-say/